Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CLXR 001

Next Previous
X
Search
Drug Profile

CLXR 001

Alternative Names: CLXR-001; Heartcel; Immunomodulatory progenitor cell therapy - Celixir; iMP cell therapy - Celixir; iMP-cells

Latest Information Update: 23 Feb 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cell Therapy Limited
  • Developer Celixir
  • Class Cardiovascular therapies; Cell therapies; Heart failure therapies; Mesenchymal stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Cardiomyopathies
  • No development reported Heart failure

Most Recent Events

  • 23 Feb 2022 No development reported - Phase-II for Heart failure (Adjuvant therapy) in Europe (Intracardiac)
  • 06 Jul 2020 Celixir suspends the ongoing phase III trial Heartcel trial in Cardiomyopathies in Europe due to COVID-19 pandemic
  • 06 Jul 2020 Celixir plans to recommence enrollment a phase II trial for Cardiomyopathies, under a new CTA in Q3 2020

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top